Resources and tools for guideline developers, health technology assessment teams and decision makers interested in rapid guidance or HTA products

DRAFT of sections to cover

Prepared by the COVID-END Recommending Working Group

1. Definition of Guidelines
   • (to provide accepted definition of CPGs and differentiate them from consensus documents)
   • Provide definitions of HTA, economic analyses, etc
   • Also provide definitions on rapid, emergent guidance, etc.
   • Also, provide definitions of Health systems guidance and public health guidelines.

2. Importance of Guidelines /guidance in COVID 19
   • Brief summary if the impact of CPGs/HTA on emergencies (why they are desirable over other documents

3. Determining the need for developing guideline/guidance on COVID 19
   • This is about some criteria for starting a new CPG/HTA development process, or considering adaptation (new evidence, a new CPG, clinical variability, etc.)
   • Adding here a flow chart of development/adaptation

4. Gathering the best guideline/HTA team
   • Recommendations for potential users about how a guideline team should be composed
   • Recommendations for potential users about how an HTA team should be composed

5. Types and models for guidance /guidelines and HTA development and deciding on the best approach for obtaining guidance and recommendations
   • Provide definitions and resources that support them: De novo development, adaptation, adoption/endorsement (CPGS) [something similar for HTA?]
   • Provide guidance on the best model for each user considering costs, time, evidence, organization constraints, capacity, etc.

6. Technology-based models and resources to support Guidelines development and updating
   • E.g., MAGIC, GRADE Pro

7. Tools needed in the CPG/HTA development for assessing the quality of the available guidelines
• Information on tools and frameworks useful for assessing, and developing Guidelines
  
i. Assessing the quality of CPGs (AGREE)
  
ii. Reporting checklists (e.g., RIGHT)
  
iii. Developing the guideline and assessing the quality of the evidence (e.g., GRADE), 4. Moving from evidence to recommendation (e.g., EtD)
  
iv. Resources for HTA?/Economic analysis (e.g., CHEERS)

8. Sources for primary studies and secondary studies (evidence synthesis)
   • Perhaps linking to the Synthesis group document

9. Sources for available CPGs
   • CPGs: Provide well known databases and platforms (e.g., ECRI, PubMed, Guideline Central, trip database)
   • HTA: INAHTA, CRD, NHS EED, EconLit, etc.

10. How to incorporate economic analysis/HTA in CPG development
    • I thought about some guidance (a paragraph?) on how to use economic evidence in the CPG development *resources,